Welcome to our dedicated page for Neogenomics SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reimbursement swings, rapid NGS test launches, and multi-site lab expansions make NeoGenomics鈥� SEC filings dense and time-sensitive. Sifting through a 300-page 10-K to find how CMS policy shifts impact oncology diagnostics revenue isn鈥檛 trivial. That鈥檚 the problem our platform solves.
Stock Titan delivers AI-powered summaries that turn every NeoGenomics annual report 10-K simplified, each NeoGenomics quarterly earnings report 10-Q filing, and even a surprise NeoGenomics 8-K material events explained into plain-English insights. Need NeoGenomics Form 4 insider transactions real-time? We stream the data the instant executives file, flagging notable moves so you can monitor NeoGenomics insider trading Form 4 transactions without refreshing EDGAR.
Here鈥檚 what you鈥檒l uncover faster than opening a PDF:
- Segment breakouts鈥擟linical Services vs. Pharma Services鈥攑ulled directly from the latest NeoGenomics earnings report filing analysis.
- Risk-factor shifts, like payer-mix concentration, highlighted by our AI with links back to source paragraphs.
- Board and leadership pay straight from the NeoGenomics proxy statement executive compensation section.
- Alerts on NeoGenomics executive stock transactions Form 4 alongside historical pattern charts.
Whether you鈥檙e understanding NeoGenomics SEC documents with AI for a deep-dive valuation model or just checking a single NeoGenomics insider trading Form 4, our real-time engine gives you comprehensive coverage of every filing type鈥�10-K, 10-Q, 8-K, S-3, DEF 14A鈥攗pdated the moment they hit EDGAR. No more CTRL-F hunts; the insights that move oncology-focused portfolios are already distilled for you.
Q2-25 results: NeoGenomics (NEO) generated net revenue of $181.3 million, up 10.2% YoY; client-direct billing remained the largest channel (72% of sales). Gross profit increased 6.6% to $77.3 million but gross margin fell 150 bp to 42.6% as cost-of-revenue growth out-paced pricing.
Expenses & earnings: Operating costs rose 32% to $124.9 million, driven by $20.0 million in impairments (InVisionFirst-Lung wind-down & planned Trapelo divestiture) plus higher G&A, R&D and sales spend. Operating loss widened to $47.6 million (-$21.9 million LY); GAAP EPS was 鈥�$0.35 vs 鈥�$0.15. 1H-25 net loss reached $71.0 million.
Liquidity & leverage: Operating cash burn improved to 鈥�$5.0 million (1H-24 鈥�$12.0 million). Cash & equivalents shrank to $154.7 million from $367.0 million after repaying the $201.3 million 1.25% 2025 converts. Balance-sheet debt now consists mainly of the $341.1 million 0.25% 2028 convertible notes; net debt rose to $186.4 million. Current ratio eased to 3.9x (FY-24 3.0x).
Strategic/other: Closed $8.3 million Pathline acquisition (adds $4.7 million 1H revenue) and classified Trapelo Health as held-for-sale. Goodwill stands at $524.1 million; intangible assets $301.8 million post-write-downs. An $11.2 million reserve remains for an ongoing OIG/DOJ investigation; patent litigation with Natera and shareholder suits remain unresolved.
NeoGenomics Director Marjorie C. Green received new equity compensation grants on June 19, 2025, consisting of:
- Stock Options: Granted 16,019 options to buy common stock at an exercise price of $6.95 per share. These options will become exercisable on June 1, 2026, and expire on June 19, 2035.
- Restricted Stock Units (RSUs): Awarded 22,964 RSUs that will vest on June 1, 2026. Once vested, these RSUs convert to common stock with no expiration date.
This Form 4 filing represents standard director compensation equity grants. The combined awards suggest continued commitment to aligning director interests with shareholders through long-term equity incentives. All securities are held directly by the reporting person.
NeoGenomics has filed a Form 3 (Initial Statement of Beneficial Ownership) announcing the appointment of Marjorie C. Green as a Director of the company, effective June 19, 2025. The filing discloses that:
- Green currently owns no securities or derivative securities of NeoGenomics
- She serves as a Director but holds no other positions (such as Officer or 10% Owner)
- The filing was submitted individually, not as part of a group
- The document was signed by Ali Olivo as Attorney-in-Fact on June 24, 2025
This Form 3 filing is a standard regulatory requirement for new company insiders under Section 16(a) of the Securities Exchange Act of 1934, establishing their initial ownership position upon assuming their role.
NeoGenomics has announced a significant board expansion and appointment in a Form 8-K filing. The company's Board of Directors has increased its size from nine to ten members with the appointment of Marjorie C. Green as a new director, effective June 19, 2025.
Key details of the appointment include:
- Ms. Green will serve until the 2026 annual meeting of stockholders or until resignation/removal
- She will receive compensation aligned with the company's existing independent director compensation program as disclosed in the 2025 proxy statement
- The appointment was publicly announced via press release on June 24, 2025
The filing, signed by EVP and General Counsel Alicia C. Olivo, includes standard regulatory disclosures and confirms that NeoGenomics is not classified as an emerging growth company. The company trades on the Nasdaq Stock Market under the symbol NEO.
FAQ
What is the current stock price of Neogenomics (NEO)?
What is the market cap of Neogenomics (NEO)?
What core services does NeoGenomics Inc offer?
How does NeoGenomics support clinical decision-making?
What sets NeoGenomics apart in the diagnostic testing industry?
In which regions does NeoGenomics operate?
What types of diagnostic tests are performed at NeoGenomics?
How does NeoGenomics ensure the accuracy and reliability of its tests?
What benefits do clients gain from NeoGenomics' technical-only testing programs?
How does NeoGenomics compare to similar diagnostic laboratories?
